JP6920207B2 - シンデカン−２のモジュレーターとその使用 - Google Patents

シンデカン−２のモジュレーターとその使用 Download PDF

Info

Publication number
JP6920207B2
JP6920207B2 JP2017550240A JP2017550240A JP6920207B2 JP 6920207 B2 JP6920207 B2 JP 6920207B2 JP 2017550240 A JP2017550240 A JP 2017550240A JP 2017550240 A JP2017550240 A JP 2017550240A JP 6920207 B2 JP6920207 B2 JP 6920207B2
Authority
JP
Japan
Prior art keywords
cindecane
cells
modulator
fragment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017550240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510879A5 (enExample
JP2018510879A (ja
Inventor
ジェイ． エリマン，スティーブン
ジェイ． エリマン，スティーブン
ローズ バークレー，ローラ
ローズ バークレー，ローラ
カバナフ，ジャック
ダフィー，マイケル
Original Assignee
オルブセン セラピューティクス リミテッド
オルブセン セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オルブセン セラピューティクス リミテッド, オルブセン セラピューティクス リミテッド filed Critical オルブセン セラピューティクス リミテッド
Publication of JP2018510879A publication Critical patent/JP2018510879A/ja
Publication of JP2018510879A5 publication Critical patent/JP2018510879A5/ja
Priority to JP2021021178A priority Critical patent/JP7288920B2/ja
Application granted granted Critical
Publication of JP6920207B2 publication Critical patent/JP6920207B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017550240A 2015-03-20 2016-03-18 シンデカン−２のモジュレーターとその使用 Active JP6920207B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021021178A JP7288920B2 (ja) 2015-03-20 2021-02-12 シンデカン－２のモジュレーターとその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15160181 2015-03-20
EP15160181.2 2015-03-20
PCT/US2016/023178 WO2016154019A1 (en) 2015-03-20 2016-03-18 Modulators of syndecan-2 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021021178A Division JP7288920B2 (ja) 2015-03-20 2021-02-12 シンデカン－２のモジュレーターとその使用

Publications (3)

Publication Number Publication Date
JP2018510879A JP2018510879A (ja) 2018-04-19
JP2018510879A5 JP2018510879A5 (enExample) 2019-04-25
JP6920207B2 true JP6920207B2 (ja) 2021-08-18

Family

ID=52780404

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017550240A Active JP6920207B2 (ja) 2015-03-20 2016-03-18 シンデカン−２のモジュレーターとその使用
JP2021021178A Active JP7288920B2 (ja) 2015-03-20 2021-02-12 シンデカン－２のモジュレーターとその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021021178A Active JP7288920B2 (ja) 2015-03-20 2021-02-12 シンデカン－２のモジュレーターとその使用

Country Status (4)

Country Link
US (2) US10124038B2 (enExample)
EP (1) EP3271396B1 (enExample)
JP (2) JP6920207B2 (enExample)
WO (2) WO2016154019A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
JP6438457B2 (ja) 2013-04-16 2018-12-12 オルブセン セラピューティクス リミテッド シンデカン−２の医療用途
US10124038B2 (en) 2015-03-20 2018-11-13 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
EP3402489B1 (en) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
CA3069805A1 (en) 2017-07-14 2019-01-17 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
US20210113654A1 (en) * 2018-05-31 2021-04-22 Yale University Methods and Compositions to Alleviate Vascular Permeability
SG11202104136YA (en) 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
US12343336B2 (en) * 2019-08-05 2025-07-01 Novocure Gmbh Increasing cancer cells' sensitivity to tumor treating fields (TTFields) by inhibiting IL11 activity
CN110628717B (zh) * 2019-10-28 2020-10-30 上海科医联创生物科技有限公司 一种浸润性t细胞的培养方法
MX2022013112A (es) 2020-04-22 2023-01-16 Dragonfly Therapeutics Inc Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc.
AU2021273980A1 (en) * 2020-05-22 2023-01-19 Yale University Methods and compositions to treat vascular leak
WO2022179518A1 (en) * 2021-02-25 2022-09-01 Rosas Ivan O Anti-fibrotic peptides and uses thereof
WO2025101747A1 (en) * 2023-11-08 2025-05-15 Vst Bio Corporation Methods and compositions for treatment of pulmonary hypertension
CN119185312B (zh) * 2024-10-11 2026-04-21 浙江大学 盐酸胺苯吖啶在制备防治纤维化疾病的药物中的应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5726058A (en) 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
AU749675B2 (en) 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
IL133318A0 (en) * 1999-12-05 2001-04-30 Yeda Res & Dev Proteoglycans and pharmaceutical compositions comprising them
US7442390B2 (en) 2000-06-05 2008-10-28 University Of South Florida Method for enhancing engraftment of cells using mesenchymal progenitor cells
WO2002087609A1 (en) 2001-05-01 2002-11-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Identification of a cell surface receptor for papillomaviruses
MXPA04005010A (es) 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
WO2003062386A2 (en) 2002-01-18 2003-07-31 Regents Of The University Of Minnesota Syndecans and angiogenesis
WO2004003179A1 (en) 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
US20040258670A1 (en) 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
WO2005037867A1 (en) * 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
EP3461884B1 (en) 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
PL1789534T3 (pl) 2004-08-16 2015-03-31 Cellresearch Corp Pte Ltd Wyodrębnienie komórek macierzystych/progenitorowych z błony owodniowej pępowiny
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2007122823A1 (ja) 2006-04-20 2007-11-01 Jichi Medical University ベクター産生型腫瘍標的細胞
US20070264239A1 (en) 2006-05-10 2007-11-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isolation of pericytes
WO2008085229A2 (en) 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
KR100883565B1 (ko) 2007-02-14 2009-02-13 (주)프로스테믹스 지방 줄기세포의 조직 재생 능력을 최적화한 조건 배지를 함유한 조직 재생용 주사제 첨가제
US20100111914A1 (en) 2007-05-21 2010-05-06 Yuanyuan Zhang Stem cells from urine and methods for using the same
KR20080103637A (ko) 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
US9289492B2 (en) 2007-07-17 2016-03-22 The General Hospital Corporation Collecting ovarian cancer stem cells from ovarian cancer cells
DK2205721T3 (en) 2007-10-17 2016-10-24 Txcell TR1 cells mesenchymal stem cells and uses thereof
WO2009105624A2 (en) 2008-02-21 2009-08-27 Massachusetts Institute Of Technology Simultaneous delivery of receptors and/or co-receptors for growth factor stability and activity
KR20100106744A (ko) 2009-03-24 2010-10-04 이화여자대학교 산학협력단 이동성 피부세포질환 또는 멜라닌 합성관련 질환 예방 또는치료용 조성물
KR101301262B1 (ko) 2009-10-23 2013-08-27 가톨릭대학교 산학협력단 ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도
EP2545928B1 (en) 2010-03-10 2016-07-20 Two Cells Co., Ltd Cell preparation containing mesenchymal stem cells, and method for producing same
US20130189275A1 (en) 2010-06-03 2013-07-25 University Of Rochester Compositions and methods for inhibition of or treatment of dengue virus infection
KR101309910B1 (ko) * 2010-08-06 2013-09-17 이화여자대학교 산학협력단 대장암 진단 및 치료제로서의 신데칸-2 펩티드 단편
US8580739B2 (en) * 2010-11-17 2013-11-12 East Carolina University Methods of reducing myocardial injury following myocardial infarction
KR20120095022A (ko) * 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
US20150030615A1 (en) 2012-03-09 2015-01-29 Verastem, Inc. Biomarkers for cancer stem cells and related methods of use
US20150125950A1 (en) 2012-05-18 2015-05-07 Agency For Science, Technology And Research (A*Sta (A*Star) Umbilical cord mesenchymal stem cell exosomes
CA2910802A1 (en) 2013-04-12 2014-10-16 Samir El Andaloussi Therapeutic delivery vesicles
JP6438457B2 (ja) * 2013-04-16 2018-12-12 オルブセン セラピューティクス リミテッド シンデカン−２の医療用途
WO2015038075A1 (en) 2013-09-16 2015-03-19 Agency For Science, Technology And Research Method
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
GB201418562D0 (en) * 2014-10-20 2014-12-03 Univ London Queen Mary Peptides
US10124038B2 (en) 2015-03-20 2018-11-13 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
EP3402489B1 (en) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
MX376974B (es) 2016-02-19 2025-03-07 Phoenix Molecular Designs Derivados de carboxamida útiles como inhibidores de rsk.
WO2018220442A2 (en) 2017-05-30 2018-12-06 Orbsen Therapeutics Limited Stromal stem cell therapeutics and methods of use
MX2021000184A (es) 2018-07-05 2021-05-12 Novobind Livestock Therapeutics Inc Anticuerpos contra agentes patogenos en aves de corral y sus aplicaciones.

Also Published As

Publication number Publication date
US11903997B2 (en) 2024-02-20
WO2016154019A1 (en) 2016-09-29
JP2021098708A (ja) 2021-07-01
EP3271396A1 (en) 2018-01-24
WO2016150884A1 (en) 2016-09-29
US10124038B2 (en) 2018-11-13
EP3271396B1 (en) 2022-03-16
US20190262421A1 (en) 2019-08-29
JP7288920B2 (ja) 2023-06-08
JP2018510879A (ja) 2018-04-19
US20160271211A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
JP6920207B2 (ja) シンデカン−２のモジュレーターとその使用
JP7480197B2 (ja) 抗ｔｒｅｍ１抗体及びその使用方法
JP2021008487A (ja) 抗ｎｋｇ２ａ抗体を使用した治療計画
US20140294765A1 (en) Lsr antibodies, and uses thereof for treatment of cancer
ES2543095T3 (es) Agentes de unión a TLR3
JP2022513778A (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
KR20190016966A (ko) 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
ES2774422T3 (es) Anticuerpos para IL-21
CN103459595B (zh) 针对人前列腺素e2受体ep4的抗体
TW202016140A (zh) Il-11ra抗體
HK1254289A1 (zh) 调控免疫反应的方法及抗体
RS63903B1 (sr) Antitela, upotrebe i metode
TW202110891A (zh) 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途
TW202110890A (zh) 抗siglec-9組合物及其用於調節骨髓細胞發炎表型之方法及用途
JP2022514499A (ja) 抗ｉｌ－２７抗体及びその使用
TW202409280A (zh) Cnx抗原結合分子
ES2957940T3 (es) Anticuerpos bispecíficos anti-PD-L1-anti-TIM-3
KR20210070303A (ko) 항-인간 cd45rc 항체 및 이의 용도
JP2021530428A (ja) 頭頸部癌の処置
CA3151078A1 (en) Anti-il-27 antibodies and uses thereof
JP2022518441A (ja) ヒトｃｄ１３７に結合する抗体の製剤およびその使用
JP2024542879A (ja) Ｐｄ－１およびｔｇｆ－ｂｒｉｉ結合ドメインを含む多重特異性結合部位
JP7357347B2 (ja) 細胞外のＰＫＣδを標的とする肝癌細胞増殖抑制剤及びそれを含む新規肝癌治療薬
WO2022132887A1 (en) Human monoclonal antibodies targeting the sars-cov-2 spike protein
WO2021011799A1 (en) Inflammatory bowel diseases therapy involving disrupting ccr9:drd5 heteromer assembly

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210212

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210212

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210406

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210726

R150 Certificate of patent or registration of utility model

Ref document number: 6920207

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250